SCYX - SCYNEXIS, Inc.
| Previous Close | 0.8400 |
| Open | 0.8159 |
| Bid | 0.7905 x 1000 |
| Ask | 0.7980 x 1100 |
| Day's Range | 0.7769 - 0.8459 |
| 52 Week Range | 0.7769 - 2.4500 |
| Volume | 89,150 |
| Avg. Volume | 274,364 |
| Market Cap | 37.517M |
| Beta (3Y Monthly) | 1.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9020 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.81 |
- Zacks•3 days ago
Scynexis (SCYX) Reports Q3 Loss, Tops Revenue Estimates
Scynexis (SCYX) delivered earnings and revenue surprises of 30.00% and 6.67%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 days ago
Scynexis: 3Q Earnings Snapshot
On a per-share basis, the Jersey City, New Jersey-based company said it had net income of 1 cent. Losses, adjusted for non-recurring gains, were 14 cents per share. The pharmaceutical company posted revenue ...
- PR Newswire•3 days ago
SCYNEXIS Reports Third Quarter 2018 Financial Results and Provides Company Update
JERSEY CITY, N.J., Nov. 13, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today ...
- PR Newswire•24 days ago
SCYNEXIS Announces FDA Agreement with Company-Proposed Phase 3 Vulvovaginal Candidiasis Program for Oral Ibrexafungerp
JERSEY CITY, N.J., Oct. 23, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced the successful completion of an End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA) for its lead product candidate, ibrexafungerp (formerly SCY-078), for patients with vulvovaginal candidiasis (VVC). The FDA has agreed with the Company's proposed overall design of the Phase 3 registration program to support approval of oral ibrexafungerp for the treatment of VVC and prevention of recurrent VVC. SCYNEXIS expects to initiate the program in the fourth quarter of 2018.
- PR Newswire•last month
SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida auris Infections (CARES)
JERSEY CITY, N.J., Oct. 15, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced the dosing of the first patient with a Candida auris infection, an emerging life-threatening and multidrug-resistant fungal pathogen, in a Phase 3 open-label study evaluating oral ibrexafungerp (formerly SCY-078) in patients with candidiasis caused by C. auris (the CARES Study). Ibrexafungerp, the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family, is in clinical development for the treatment of multiple serious fungal infections, including vulvovaginal candidiasis (VVC), invasive candidiasis (IC), invasive aspergillosis (IA) and refractory invasive fungal infections.
- PR Newswire•2 months ago
SCYNEXIS Supports AMR Challenge and Fungal Disease Awareness Week
-- HHS and CDC Lead Efforts Aim to Combat Antimicrobial Resistance, Raise Awareness of Fungal Diseases -- JERSEY CITY, N.J. , Oct. 1, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ : SCYX), a biotechnology ...
- PR Newswire•2 months ago
SCYNEXIS to Present an Overview of the Company's Pipeline at IDWeek 2018
JERSEY CITY, N.J. , Sept. 26, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today ...
- PR Newswire•2 months ago
SCYNEXIS, Inc. to Present at Upcoming Investor Conferences
JERSEY CITY, N.J. , Sept. 25, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today ...
- Simply Wall St.•2 months ago
Who Owns SCYNEXIS Inc (NASDAQ:SCYX)?
A look at the shareholders of SCYNEXIS Inc (NASDAQ:SCYX) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to seeRead More...
- InvestorPlace•3 months ago
5 Healthcare Stocks That Are Down, But Not Out!
Few investment sectors arouse sharply divided opinion quite like healthcare stocks. This segment features incredible volatility as poor clinical trials could devastate individual companies. During the campaign trail for the 2016 presidential election, then-real-estate-mogul Donald Trump lashed out against pharmaceuticals.
- PR Newswire•3 months ago
SCYNEXIS, Inc. to Participate in Upcoming Investor Conferences
JERSEY CITY, N.J. , Aug. 29, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today ...
- Zacks•3 months ago
Scynexis (SCYX) Reports Q2 Loss, Lags Revenue Estimates
Scynexis (SCYX) delivered earnings and revenue surprises of -64.29% and -20.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 months ago
Scynexis: 2Q Earnings Snapshot
On a per-share basis, the Jersey City, New Jersey-based company said it had a loss of 23 cents. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
- PR Newswire•3 months ago
SCYNEXIS Reports Second Quarter 2018 Financial Results and Provides Company Update
Oral dose regimen of ibrexafungerp (formerly SCY-078) identified for Phase 3 VVC development; Phase 3 on track for initiation in the fourth quarter of 2018 Development of ibrexafungerp intravenous (IV) ...
- ACCESSWIRE•4 months ago
Free Daily Technical Summary Reports on Mylan and Three Other Generic Drugs Stocks
Losses were broad based as all sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Drugs - Generic stocks: The Medicines Co. (NASDAQ: MDCO), Mylan N.V. (NASDAQ: MYL), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), and SCYNEXIS Inc. (NASDAQ: SCYX).
- PR Newswire•4 months ago
The World Health Organization Recognizes New Antifungal Class by Granting "ibrexafungerp" to SCYNEXIS as the International Non-Proprietary Name for SCY-078
New WHO INN stem "-fungerp" signifies a novel class of antifungals Novel generic name highlights the unique attributes of SCY-078 and its potential to address significant unmet needs across multiple ...
Market Realist•4 months agoWhy Scynexis Stock Rose 16.4% Yesterday
Yesterday, Scynexis (SCYX) stock rose 16.4% on the announcement of positive data from its Phase 2b clinical trial of its drug candidate SCY-078 for the treatment of VVC (vulvovaginal candidiasis), or vaginal yeast infection. The findings were compared to treatment results for the standard of care drug Flu (fluconazole). Currently, the SCY-078 candidate is also being developed and evaluated for the treatment of a number of other serious fungal infections, including invasive candidiasis, invasive aspergillosis, and refractory invasive fungal infections. Currently, the only approved oral drug for the treatment of VVC is fluconazole, whereas there are no approved products for patients with recurrent VVC.
- PR Newswire•4 months ago
SCYNEXIS Reports Positive Results from Phase 2b Dose-Finding Study of Oral SCY-078 in Vulvovaginal Candidiasis
Clinically and mycologically effective and well-tolerated oral dose of SCY-078 identified for use in Phase 3 registration program Results confirm strong clinical activity of oral SCY-078 and suggest improved ...
- ACCESSWIRE•5 months ago
Complimentary Technical Snapshots on Mylan and Three More Generic Drugs Stocks
Ahead of today's trading session, WallStEquities.com assesses Mylan N.V. (NASDAQ: MYL), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), SCYNEXIS Inc. (NASDAQ: SCYX), and The Medicines Co. (NASDAQ: MDCO). The biggest catalyst of the Generic Drugs industry is the significantly lower price of generics compared to branded drugs.
- PR Newswire•5 months ago
SCYNEXIS Announces the Presentation of SCY-078 Data at the Teratology Society 58th Annual Meeting
JERSEY CITY, N.J., June 27, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (SCYX), a biotechnology company developing innovative therapies for difficult-to-treat and often life-threatening infections, today announced the presentation of data at the Teratology Society 58th Annual Meeting, June 23-27, 2018 in Clearwater, Florida. SCY-078, the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family, is in clinical development for the treatment of multiple serious fungal infections, including vulvovaginal candidiasis (VVC), invasive candidiasis (IC), invasive aspergillosis (IA) and refractory invasive fungal infections. "The treatment of fungal infections during pregnancy has long been challenging due to the well-known developmental toxicities associated with existing antifungal treatments," said David Angulo, M.D., Chief Medical Officer of SCYNEXIS.
- PR Newswire•5 months ago
SCYNEXIS to Present SCY-078 Data at Three Scientific Meetings in June/July 2018
20th International Symposium on Infections in the Immunocompromised Host (ICHS) Teratology Society 58th Annual Meeting 20th Congress of the International Society for Human and Animal Mycology (ISHAM) JERSEY ...
- PR Newswire•5 months ago
SCYNEXIS Presents SCY-078 Data at ASM Microbe 2018
SCY-078 demonstrates potent in vitro activity vs. echinocandin-resistant Candida strains and synergistic activity with isavuconazole vs. Aspergillus spp. SCY-078 exhibits a profound effect on cellular ...
- PR Newswire•5 months ago
Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018
88 Presentations by Coalition Members During the Annual Meeting WASHINGTON , June 6, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that 13 of its member companies will present ...
- PR Newswire•5 months ago
SCYNEXIS Announces the Publication of Phase 1 Study Results for SCY-078 in The Journal of Clinical Pharmacology
JERSEY CITY, N.J., June 6, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (SCYX), a biotechnology company developing innovative therapies for difficult-to-treat and often life-threatening infections, today announced the publication of results from a Phase 1 study of SCY-078, assessing the risk for drug-drug interactions when administered with drugs metabolized by the CYP family of enzymes, in The Journal of Clinical Pharmacology. SCY-078, the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family, is in clinical development for the treatment of multiple serious fungal infections, including vulvovaginal candidiasis (VVC), invasive candidiasis (IC), invasive aspergillosis (IA) and refractory invasive fungal infections. The article, "Lack of Impact by SCY-078, a First-in-Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug-Drug Interactions," describes the Phase 1 study, in which the pharmacokinetic parameters of rosiglitazone, a thiazolidinedione agent commonly used for type 2 diabetes, were measured in the absence and presence of SCY-078 dosed to therapeutically relevant levels in healthy adult subjects.
- PR Newswire•6 months ago
SCYNEXIS to Present SCY-078 Data at ASM Microbe 2018
JERSEY CITY, N.J. , May 24, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today ...
